Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study

Few population-based analyses have investigated survival change in glioblastoma multiforme (GBM) patients treated with concomitant radiotherapy-temozolomide (RT-TMZ) and adjuvant temozolomide (TMZ) and then bevacizumab (BEV) after Food and Drug Administration (FDA) approval, respectively. We aimed t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Zhu, Ping, Du, Xianglin L., Lu, Guangrong, Zhu, Jay-Jiguang
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2017
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546458/
https://ncbi.nlm.nih.gov/pubmed/28467795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17054
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia